Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Vascular

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 0 · 0%High 0 · 0%

All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis

Idrabiotaparinux showed no clear difference in all‐cause mortality compared with idraparinux (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.48 [0.18, 1.27]
1 study · 757 participants
Low

Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis

It is very uncertain whether idrabiotaparinux changes all harmful effects compared with idraparinux (very low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.92 [0.83, 1.02]
1 study · 757 participants
Very low

Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis

Idrabiotaparinux showed no clear difference in recurrent venous thromboembolism compared with idraparinux (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.72 [0.31, 1.69]
1 study · 757 participants
Low

Major bleeding during the initial treatment ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

Idrabiotaparinux may leads to lower major bleeding compared with idraparinux (low certainty).

1 finding from 1 review

Pentasaccharides for the treatment of deep vein thrombosis 2017 · Cochrane Headline outcomes only
RR 0.21 [0.06, 0.71]
1 study · 755 participants
Low